Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J De Knegt

Showing results (1-10 of 168) with videos related to

Pageof 17
Sort By:
Scandinavian Journal of Gastroenterology. Supplement|June 20, 2006
Current therapy of hepatitis CRobert J de Knegt
Scandinavian Journal of Gastroenterology. Supplement|June 20, 2006
Non-invasive measurement of liver fibrosis: application of the FibroScan in hepatologyClaudia Verveer, Robert J de Knegt
Transplantation|January 4, 2017
The Path to Cancer and Back: Immune Modulation During Hepatitis C Virus Infection, Progression to Fibrosis and Cancer, and Unexpected Roles of New AntiviralsJose D Debes, Robert J de Knegt, Andre Boonstra
Drugs|October 27, 2015
Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic StrategiesRaoel Maan, Robert J de Knegt, Bart J Veldt
Hepatology (Baltimore, Md.)|July 1, 2022
Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortalityLaurens A van Kleef, Robert J de Knegt, Willem Pieter Brouwer
The American Journal of Gastroenterology|December 14, 2021
Objectively Measured Physical Activity Is Inversely Associated With Nonalcoholic Fatty Liver Disease: The Rotterdam StudyLaurens A van Kleef, Amy Hofman, Trudy Voortman, et al.
Journal of Hepatology|June 22, 2010
Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis CRobert Roomer, Bettina E Hansen, Harry L A Janssen, et al.
Hepatology (Baltimore, Md.)|September 11, 2010
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis CRobert Roomer, Bettina E Hansen, Harry L A Janssen, et al.
Scientific Reports|September 8, 2021
Sex-specific normal values and determinants of infrarenal abdominal aortic diameter among non-aneurysmal elderly populationFang Zhu, Banafsheh Arshi, M Arfan Ikram, et al.
World Journal of Gastroenterology|November 28, 2012
Telaprevir/boceprevir era: from bench to bed and backQiuwei Pan, Maikel P Peppelenbosch, Harry L A Janssen, et al.
Pageof 17

Showing results (1-10 of 168) with videos related to

Sort By:
Pageof 17
Scandinavian Journal of Gastroenterology. Supplement|June 20, 2006
Current therapy of hepatitis CRobert J de Knegt
Scandinavian Journal of Gastroenterology. Supplement|June 20, 2006
Non-invasive measurement of liver fibrosis: application of the FibroScan in hepatologyClaudia Verveer, Robert J de Knegt
Transplantation|January 4, 2017
The Path to Cancer and Back: Immune Modulation During Hepatitis C Virus Infection, Progression to Fibrosis and Cancer, and Unexpected Roles of New AntiviralsJose D Debes, Robert J de Knegt, Andre Boonstra
Drugs|October 27, 2015
Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic StrategiesRaoel Maan, Robert J de Knegt, Bart J Veldt
Hepatology (Baltimore, Md.)|July 1, 2022
Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortalityLaurens A van Kleef, Robert J de Knegt, Willem Pieter Brouwer
The American Journal of Gastroenterology|December 14, 2021
Objectively Measured Physical Activity Is Inversely Associated With Nonalcoholic Fatty Liver Disease: The Rotterdam StudyLaurens A van Kleef, Amy Hofman, Trudy Voortman, et al.
Journal of Hepatology|June 22, 2010
Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis CRobert Roomer, Bettina E Hansen, Harry L A Janssen, et al.
Hepatology (Baltimore, Md.)|September 11, 2010
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis CRobert Roomer, Bettina E Hansen, Harry L A Janssen, et al.
Scientific Reports|September 8, 2021
Sex-specific normal values and determinants of infrarenal abdominal aortic diameter among non-aneurysmal elderly populationFang Zhu, Banafsheh Arshi, M Arfan Ikram, et al.
World Journal of Gastroenterology|November 28, 2012
Telaprevir/boceprevir era: from bench to bed and backQiuwei Pan, Maikel P Peppelenbosch, Harry L A Janssen, et al.
Pageof 17